Clinical Trial Update: A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. [Phase 3]

View source ↗

Summary

Phase 3 long-term safety study of long-acting injectable risperidone in schizophrenia or schizoaffective disorder patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: Janssen, LP | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED